authorization-for-the-use-and-disclosure-of-phi-and-instructions.pdf
... , NY, NY 10003 FGP Radiology: NYU Langone Health Radiology Medical Records, 650 First Avenue, 4th Floor ... of the information to be released: ☐Entire medical record from the provider/entity indicated above ☐Records related ...
hie-fact-sheet-and-consent-polish.pdf
... Participants”) and non-NYU Langone health providers who may request access to your medical records for purposes ... of current treatment (“Care Everywhere Providers”) to obtain access to your medical records through ...
authorization-for-the-use-and-disclosure-of-phi-instructions-2025.pdf
... Radiology: NYU Langone Health Radiology Medical Records, 650 First Avenue, 4th Floor, NY, NY 10016 All other ... you want to release records from (see instructions page ): NYU Langone Health NYU Langone Hospitals ...
REBYOTA for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study
This is a prospective observational cohort study designed to collect data on patients who received REBYOTA for the prevention of rCDI in the routine care setting. As all data collected for this study are observational, the decision to prescribe REBYOTA is at the treating physician’s discretion and independent from the decision to enroll the patient in the study. Adult patients who receive a prescription for REBYOTA to prevent rCDI are eligible to enroll according to the inclusion and exclusion criteria described below. Patients must enroll in the study between prescription and administration. This allows time for patients to enroll while still conducting the baseline measurement of patient-reported outcomes (CDI-DaySyms™) prior to administration. REBYOTAFor each patient, the current or presenting rCDI episode will be defined as the CDI episode just prior to receiving REBYOTA. If a patient receives REBYOTA more than once, the first dose will be used to define the presenting rCDI and to assess REBYOTA effectiveness.Baseline period will be defined as the time period between the date REBYOTA is prescribed and the date REBYOTA is administered.Data will be collected from patients’ medical records after obtaining informed consent. Data about clinical history, CDI events (primary and recurrent: severity, treatment), CDI-related symptoms, treatments, medical procedures, AEs, and healthcare resource utilization (i.e., hospitalizations and re-admissions) will be collected through 6 months of follow-up from the date of REBYOTA administration.
International Patient Services | NYU Langone Health
International Patient Services at NYU Langone provides support and information to people traveling from abroad for medical care.
hie-fact-sheet-and-consent-arabic.pdf
... ://health-connect.med.nyu.edu/ (“HIE Participants”) and non-NYU Langone health providers who may request access to your medical records ... for purposes of current treatment (“Care Everywhere Providers”) to obtain access to your medical records ...
hie-fact-sheet-and-consent-russian.pdf
... ://health-connect.med.nyu.edu/ (“HIE Participants”) and non-NYU Langone health providers who may request access to your medical records ... for purposes of current treatment (“Care Everywhere Providers”) to obtain access to your medical records ...
Diagnosing Arrhythmias in Children | NYU Langone Health
Heart specialists at Hassenfeld Children’s Hospital can diagnose an arrhythmia before a baby is born, during infancy, or later in childhood.
hie-fact-sheet-and-consent-bangla.pdf
... ”) and non-NYU Langone health providers who may request access to your medical records for purposes ... of current treatment (“Care Everywhere Providers”) to obtain access to your medical records through ...
hie-fact-sheet-and-consent-yiddish.pdf
... providers who may request access to your medical records for purposes of current treatment (“Care Everywhere ... Providers”) to obtain access to your medical records through a computer network operated by the HIE ...